ConductScience.org, home

Comparison · NCT03941288-2f2ea719

Functional Dyspepsia - Cannabidiol vs Functional Dyspepsia - Placebo: Weekly Global Symptom Assessment

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Functional Dyspepsia - Cannabidiol vs Functional Dyspepsia - Placebo: Weekly Global Symptom Assessment. Trial comparisons, record NCT03941288-2f2ea719. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03941288-2f2ea719

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.480.30.665wilson
Risk in group 20.4780.2920.67wilson
Risk difference, group 1 minus group 20.00174-0.2610.264newcombe hybrid score
Risk ratio, group 1 over group 210.5561.81log
Odds ratio, group 1 over group 21.010.3243.13log
Number needed to treat, for one more participant with the outcome on Functional Dyspepsia - Cannabidiol than on Functional Dyspepsia - Placebo575from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Functional Dyspepsia - Cannabidiol
Cannabidiol will be administered to participants with functional dyspepsia orally twice daily in equally divided doses starting at 2.5mg/kg per day and increasing by 2.5 to 5.0mg/kg every other day until the target dose of 20mg/kg is reached.
1225OG000
Group 2Functional Dyspepsia - Placebo
Placebo will be administered to participants with functional dyspepsia orally twice daily in equally divided doses starting at 2.5mg/kg per day and increasing by 2.5 to 5.0mg/kg every other day until the target dose of 20mg/kg is reached.
1123OG001

Outcome

Type
SECONDARY
Title
Weekly Global Symptom Assessment
Description
The number of functional dyspepsia participants who confirmed adequate relief of dyspepsia symptoms, based on the self-reporting question In the past 7 days have you had adequate relief of your upper abdominal pain or discomfort?.
Time frame
4 weeks
Population

Source ClinicalTrials.gov

Trial

Title
Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
NCT number
NCT03941288
Phases
PHASE2
Conditions
Gastroparesis, Dyspepsia
Interventions
Cannabidiol, placebo
Lead sponsor
Mayo Clinic
Results first posted
2024-02-13

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03941288-2f2ea719